The opportunities for Next Generation Sequencing (NSG) as a diagnostic tool are immense
Next-Generation Sequencing from Research to the Clinic
In this GEN Market & Tech Analysis report we examine the trajectory of next-generation sequencing(NGS) as it migrates from the research environment toward the clinic.
Highlights of this report:
- The NGS field received a major boost with the first U.S. FDA approval granted to Illumina’s MiSeqDx system.
- This development will further drive forward the deployment of NGS for clinical testing and result in more publications in this field with clinical samples.
- Even though cancer is the major driver of the NGS space currently in the clinical segment, this will expand to include other disease areas, most notably in the case of genetic diseases as well as infectious agent characterization.
- The migration toward the clinic means that more clinical tests using NGS for mutation analysis are predicted downstream.